Coinfection and superinfection in SARS-CoV-2 pneumonia. Two underestimated threats. The need of empirical treatment under debate.
作者信息
Crespo Rafael Zaragoza, Hernández-Garcés Héctor
机构信息
Intensive Care Unit, Hospital Universitario Dr. Peset, Valencia, Spain.
Intensive Care Unit, Hospital Universitario Dr. Peset, Valencia, Spain.
出版信息
Enferm Infecc Microbiol Clin (Engl Ed). 2022 Apr;40(4):155-157. doi: 10.1016/j.eimce.2022.02.011.
Abstract
摘要
相似文献
1
Coinfection and superinfection in SARS-CoV-2 pneumonia. Two underestimated threats. The need of empirical treatment under debate.新型冠状病毒肺炎中的合并感染和重叠感染。两个被低估的威胁。经验性治疗的必要性存在争议。
Enferm Infecc Microbiol Clin (Engl Ed). 2022 Apr;40(4):155-157. doi: 10.1016/j.eimce.2022.02.011.
2
Coinfection and superinfection in SARS-CoV-2 pneumonia. Two underestimated threats. The need of empirical treatment under debate.新型冠状病毒肺炎中的合并感染和重叠感染。两种被低估的威胁。经验性治疗的必要性存在争议。
Enferm Infecc Microbiol Clin. 2022 Apr;40(4):155-157. doi: 10.1016/j.eimc.2022.02.002. Epub 2022 Mar 1.
3
Superinfection with difficult-to-treat bacteria in COVID-19 patients: a call for compliance with diagnostic and antimicrobial stewardship.新冠病毒感染患者中出现难以治疗的细菌重叠感染：呼吁遵守诊断和抗菌药物管理规范。
Intern Emerg Med. 2021 Apr;16(3):789-791. doi: 10.1007/s11739-020-02537-3. Epub 2020 Nov 22.
4
Understanding the role of bacterial and fungal infection in COVID-19.了解细菌和真菌感染在新冠病毒病中的作用。
Clin Microbiol Infect. 2021 Jan;27(1):9-11. doi: 10.1016/j.cmi.2020.09.025. Epub 2020 Oct 9.
5
COVID-19 pneumonia and the appropriate use of antibiotics.新型冠状病毒肺炎与抗生素的合理使用。
Lancet Glob Health. 2020 Dec;8(12):e1453-e1454. doi: 10.1016/S2214-109X(20)30444-7. Epub 2020 Nov 11.
6
Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial.COVID-19 或流感肺炎插管患者的早期细菌鉴定：一项欧洲多中心临床比较试验。
Am J Respir Crit Care Med. 2021 Sep 1;204(5):546-556. doi: 10.1164/rccm.202101-0030OC.
7
Resurgence of SARS-CoV-2 Delta after Omicron variant superinfection in an immunocompromised pediatric patient.奥密克戎变异株超感染后免疫功能低下的儿科患者中 SARS-CoV-2 Delta 的再现。
Virol J. 2023 Oct 27;20(1):246. doi: 10.1186/s12985-023-02186-w.
8
Unusual SARS-CoV-2 intrahost diversity reveals lineage superinfection.宿主内罕见的 SARS-CoV-2 多样性揭示了谱系超感染。
Microb Genom. 2022 Mar;8(3). doi: 10.1099/mgen.0.000751.
9
Evaluation of superinfection, antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19 patients: A cohort study in Shanghai.评价 COVID-19 患者中的超级感染、抗菌药物使用和气道微生物组与宏基因组测序：上海的一项队列研究。
J Microbiol Immunol Infect. 2021 Oct;54(5):808-815. doi: 10.1016/j.jmii.2021.03.015. Epub 2021 Apr 6.
10
Analysis of coexisting pathogens in nasopharyngeal swabs from COVID-19.分析新冠病毒鼻咽拭子中的共感染病原体。
Front Cell Infect Microbiol. 2023 Jun 22;13:1140548. doi: 10.3389/fcimb.2023.1140548. eCollection 2023.
引用本文的文献
1
Major alteration of lung microbiome and the host responses in critically ill COVID-19 patients with high viral load.重症 COVID-19 患者病毒载量高时肺部微生物组和宿主反应的重大改变。
Sci Rep. 2024 Nov 12;14(1):27637. doi: 10.1038/s41598-024-78992-1.
2
Major alteration of Lung Microbiome and the Host Reaction in critically ill COVID-19 Patients with high viral load.高病毒载量的危重症COVID-19患者肺部微生物群及宿主反应的重大改变
Res Sq. 2024 Mar 8:rs.3.rs-3952944. doi: 10.21203/rs.3.rs-3952944/v1.
本文引用的文献
1
Bacteremia during COVID-19 pandemic in a tertiary hospital in Spain.西班牙一家三级医院在 COVID-19 大流行期间的菌血症。
Enferm Infecc Microbiol Clin (Engl Ed). 2022 Apr;40(4):183-186. doi: 10.1016/j.eimce.2021.01.007.
2
The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature.在 2019 冠状病毒病大流行期间预防和控制耐多药生物体和耳念珠菌爆发的挑战：耐碳青霉烯鲍曼不动杆菌爆发报告和文献系统评价。
Antimicrob Resist Infect Control. 2022 Jan 21;11(1):12. doi: 10.1186/s13756-022-01052-8.
3
Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units.COVID-19 重症患者在重症监护病房中的管理建议。
Med Intensiva (Engl Ed). 2022 Feb;46(2):81-89. doi: 10.1016/j.medine.2021.11.019. Epub 2021 Dec 10.
4
Management of infectious complications associated with coronavirus infection in severe patients admitted to ICU.重症监护病房收治的冠状病毒感染患者感染相关并发症的管理。
Med Intensiva (Engl Ed). 2021 Nov;45(8):485-500. doi: 10.1016/j.medine.2021.08.013. Epub 2021 Aug 24.
5
Bacterial/fungal infection in hospitalized patients with COVID-19 in a tertiary hospital in the Community of Castilla y León, Spain.西班牙卡斯蒂利亚-莱昂自治区一家三级医院中新冠肺炎住院患者的细菌/真菌感染情况。
Enferm Infecc Microbiol Clin (Engl Ed). 2020 Dec 3;40(4):158-65. doi: 10.1016/j.eimc.2020.11.003.
6
Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study.新型冠状病毒感染与呼吸机相关性下呼吸道感染发病率的关系：一项欧洲多中心队列研究。
Intensive Care Med. 2021 Feb;47(2):188-198. doi: 10.1007/s00134-020-06323-9. Epub 2021 Jan 3.
7
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.定义和管理新型冠状病毒肺炎相关肺曲霉病：2020年欧洲临床微生物与感染性疾病学会/国际人类与动物真菌学会研究和临床指南共识标准
Lancet Infect Dis. 2021 Jun;21(6):e149-e162. doi: 10.1016/S1473-3099(20)30847-1. Epub 2020 Dec 14.
8
High rate of infections during ICU admission of patients with severe SARS-CoV-2 pneumonia: A matter of time?重症 SARS-CoV-2 肺炎患者入住重症监护病房期间感染率高：只是时间问题？
J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2020.12.001. Epub 2020 Dec 5.
9
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Feb;27(2):215-227. doi: 10.1016/j.cmi.2020.10.036. Epub 2020 Nov 5.
10
Low incidence of co-infection, but high incidence of ICU-acquired infections in critically ill patients with COVID-19.在新冠肺炎危重症患者中，合并感染发生率低，但重症监护病房获得性感染发生率高。
J Infect. 2021 Feb;82(2):e20-e21. doi: 10.1016/j.jinf.2020.09.010. Epub 2020 Sep 19.
Zotero 插件